A cancer drugmaker and a biotech developing a treatment for the most common form of hearing loss are both planning to go public. For one, that means disclosing the death of a person involved in one of its clinical trials.
Boston-based oncology startup Aprea Therapeutics and Woburn-based hearing loss startup Frequency Therapeutics laid out plans to raise $86.25 million and $100 million, respectively, in documents recently filed with the FDA.
